- The enrollment of the first P-III study is currently underway & has reached 85% of its enrollment goal. In a P-II study of 336 patients, NOV03 met its 1EP of efficacy i.e. improvement of total corneal fluorescein staining over control @8wks.
- Additionally, NOV03 showed improvement of certain symptoms, such as severity & frequency of dryness & burning/stinging of the eyes, over the entire duration of the P-II study with no notable safety events
- NOV03 is an investigational, water-free & preservative-free solution, based on patented EyeSol technology from Novaliq
Click here to read full press release/ article | Ref: PRNewswire | Image: SPJNews